{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:00:52Z","timestamp":1785132052454,"version":"3.55.0"},"reference-count":14,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) is the most common autoimmune blistering disease and primarily affects the elderly. Systemic corticosteroids and immunosuppressive drugs are the standard treatment, but side effects often restrict their use. Doxycycline has been proposed as an alternative, but there is limited long\u2010term, real\u2010world data on its efficacy and tolerability. We aimed to evaluate the effectiveness and length of doxycycline treatment in BP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective, single\u2010center study analyzed data from patients with a confirmed BP diagnosis treated with doxycycline. The comprehensive dataset included information on disease severity, concomitant therapies, and treatment response. Treatment duration was analyzed using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 102 patients with a mean age of 79 (range 51\u201395) years. A clinical response (an improvement of 1 or 2 on the PGA score, which ranges from 2 to \u20132) was observed in 85 patients (83.3 %), many of whom received combination therapy with other drugs (67.7 %). The median length of doxycycline treatment was 122.7\u00a0weeks. Adverse events, mainly of gastrointestinal origin, were rare,\u00a0non\u2010serious and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Doxycycline proved to be an effective and well\u2010tolerated long\u2010term treatment for elderly patients with BP, when used either as monotherapy or in combination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ddg.70313","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:32:01Z","timestamp":1785130321000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect and length of doxycycline administration in elderly patients with bullous pemphigoid"],"prefix":"10.1111","author":[{"given":"Alena","family":"Merkel\u2010Ropele","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Salmhofer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-9444","authenticated-orcid":false,"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"issue":"2","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jdv.20313","article-title":"Bullous pemphigoid burden of disease, management and unmet therapeutic needs","volume":"39","author":"Werth VP","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of Bullous pemphigoid: Overview and potential explanations","volume":"5","author":"Kridin K","year":"2018","journal-title":"Front Med"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt E","year":"2013","journal-title":"Lancet"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori L","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1159351","article-title":"Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid00","volume":"14","author":"Rosi\u2010Schumacher M","year":"2023","journal-title":"Front Immunol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40520-015-0459-4","article-title":"Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department","volume":"28","author":"Pietkiewicz P","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: A prospective case\u2010control study","volume":"131","author":"Bastuji\u2010Garin S","year":"2011","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_9_1","article-title":"Interventions for bullous pemphigoid","volume":"2","author":"Singh S","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non\u2010inferiority, randomised controlled trial","volume":"389","author":"Williams HC","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-021-02216-z","article-title":"Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta\u2010analysis","volume":"314","author":"Jin XX","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jare.2022.03.019","article-title":"Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease","volume":"44","author":"Belheouane M","year":"2023","journal-title":"J Adv Res"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212551","article-title":"The gut microbiome in bullous pemphigoid: implications of the gut\u2010skin axis for disease susceptibility","volume":"14","author":"Liu X","year":"2023","journal-title":"Front Immunol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(17)31808-1","article-title":"The BLISTER study: possible overestimation of tetracycline efficacy","volume":"390","author":"Sladden MJ","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen F","year":"2014","journal-title":"Biol Chem"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.70313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:32:03Z","timestamp":1785130323000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.70313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":14,"alternative-id":["10.1111\/ddg.70313"],"URL":"https:\/\/doi.org\/10.1111\/ddg.70313","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"2025-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ddg.70313"}}